Rifampin: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
* Adverse effects include [[Adverse drug reaction::drug-drug interactions]], [[Adverse drug reaction::rash]], [[Adverse drug reaction::hepatitis]], [[Adverse drug reaction::influenza-like illness]], [[Adverse drug reaction::neutropenia]], and [[Adverse drug reaction::thrombocytopenia]] |
* Adverse effects include [[Adverse drug reaction::drug-drug interactions]], [[Adverse drug reaction::rash]], [[Adverse drug reaction::hepatitis]], [[Adverse drug reaction::influenza-like illness]], [[Adverse drug reaction::neutropenia]], and [[Adverse drug reaction::thrombocytopenia]] |
||
* Avoid in liver failure |
* Avoid in liver failure |
||
== Dosing == |
|||
* As adjunct to fluoroquinolone for [[Staphylococcus aureus]]: |
|||
** Weight <60 kg: 600 mg p.o. daily |
|||
** Weight >60 kg: 450 mg p.o. twice daily |
|||
[[Category:Rifamycins]] |
[[Category:Rifamycins]] |
||
Revision as of 20:29, 30 August 2022
- Inhibits bacterial DNA-dependent RNA polymerase
- Never given alone due to rapid resistance
- Adverse effects include drug-drug interactions, rash, hepatitis, influenza-like illness, neutropenia, and thrombocytopenia
- Avoid in liver failure
Dosing
- As adjunct to fluoroquinolone for Staphylococcus aureus:
- Weight <60 kg: 600 mg p.o. daily
- Weight >60 kg: 450 mg p.o. twice daily
References
- ^ Gousia Dhhar, Jeanine McColl, Ian Kitai, Deborah M. Levy, Ruud H.J. Verstegen. Rifampin-induced flu-like syndrome with shock in a patient with tuberculosis infection. Canadian Medical Association Journal. 2023;195(34):E1151-E1153. doi:10.1503/cmaj.230317.
